Fig. 1: Overview of clinicopathological characteristics and clinical outcome of oncogene-mutant NSCLC treated with neoadjuvant immunotherapy.

a Overview of clinicopathological charteristics and clinical outcome of oncogene-mutant NSCLC treated with neoadjuvant immunotherapy. Clinicopathological charateristics including smoking status, therpeutic regimens, PD-L1 expression, treatment duration and preoperative radiologic response (according to Response Evaluation Criteria in Solid Tumors [RECIST]) were annotated for each patients. The horizontal dash line indicates the threshold for a major pathological response (90% regression). Pathological regression was presented in colored bar plot regarding different oncogene mutation. b Correlation between radiological shrinkage and pathological regression. Spearman correlation was used to measure the relevance. c Association between PD-L1 expression and MPR status. Centre line represents the median value of PD-L1 expression. Error bars represent the upper and lower quartiles of PD-L1 expression and whiskers defines the minimal and maximun value. PD Progression disease, SD Stable disease, PR Partial response, MPR Major pathological response, pCR Pathological complete response. d Disease-free survival (DFS) of all patients, EGFR-mutant patients and KRAS-mutant patients treated with neoadjuvant immunotherapy through Kaplan-Meier survival analysis.